About Tokyo Women's Medical University Hospital
東京女子医科大学病院 は、東京都新宿区河田町にある大学病院である。略称：女子医大病院、TWMUH。東京女子医科大学河田町キャンパスに併設されている。
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Clinical Trials at Tokyo Women's Medical University Hospital
During the past decade, Tokyo Women's Medical University Hospital conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 18 clinical trials were completed, i.e. on
average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 13 clinical trials were completed. i.e. 92.9%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Tokyo Women's Medical University Hospital" #1 sponsor was "Bayer" with 6 trials, followed by "Janssen Research & Development, LLC" with 4 trials
sponsored, "Boston Scientific Corporation" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc."
with 3 trials sponsored. Other sponsors include 20 different institutions and
companies that sponsored additional 23 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Women's Medical University Hospital"
#1 collaborator was "Duke Clinical Research Institute" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Maruishi Pharmaceutical" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Canadian VIGOUR Centre" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were
collaborators in the rest 12 trials.
Clinical Trials Conditions at Tokyo Women's Medical University Hospital
According to Clinical.Site data, the most researched conditions in "Tokyo Women's Medical University Hospital" are
"Heart Failure" (3 trials), "Coronary Artery Disease" (2 trials), "Juvenile Idiopathic Arthritis" (2 trials), "Advanced Renal Cell Carcinoma" (1 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "Tokyo Women's Medical University Hospital" in a lesser frequency.
Clinical Trials Intervention Types at Tokyo Women's Medical University Hospital
Most popular intervention types in "Tokyo Women's Medical University Hospital" are "Drug" (35 trials), "Device" (10 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (10 trials), "Axitinib (AG-013736)" (2 trials), "Baricitinib" (2 trials), "Dexmedetomidine" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Tokyo Women's Medical University Hospital
The vast majority of trials in "Tokyo Women's Medical University Hospital" are
41 trials for "All" genders and 3 trials for "Female" genders.
Clinical Trials Status at Tokyo Women's Medical University Hospital
Currently, there are NaN active trials in "Tokyo Women's Medical University Hospital".
undefined are not yet recruiting,
10 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 23 completed trials in Tokyo Women's Medical University Hospital,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Tokyo Women's Medical University Hospital, 0 "Phase 1"
clinical trials were conducted, 9 "Phase 2" clinical
trials and 28 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 6 trials that are defined as “Not Applicable".